Los puntos clave no están disponibles para este artículo en este momento.
GDF-15 captures distinct aspects of CV disease development, progression, and prognosis, which are not represented by clinical risk predictors and other biomarkers. The usefulness of GDF-15 to guide management decisions and discover new treatment targets should be further explored.
Wollert et al. (Wed,) studied this question.